Oncology Trials

Trials

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥1%

Sponsor: Bristol-Myers Squibb
NCT06561386

Learn More

 

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Janssen Research & Development, LLC
NCT06667076

Learn More

 

 

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients 

A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3) 

Sponsor: Summit Therapeutics
NCT05899608

Learn More

 
 
 

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (HARMONi-7) 

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression

Sponsor: Summit Therapeutics 

NCT06767514
 
Learn More
 
 
 

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/​INTerpath-009) 

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC 
NCT06623422 
 
Learn More
 
 
 

A study to evaluate the clinical validity of a ctDNA-based MRD test designed to detect breast cancer progression or recurrence following surgery

MONITOR-Breast: Monitoring cell-free tumor DNA as a marker of recurrence in Breast Cancer

Sponsor: Myriad Genetics

 

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (EVOKE-SCLC-04)

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC

Sponsor: Gilead Sciences
NCT06801834 
 
 
 
 

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/​HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer 

Sponsor: Merck Sharp & Dohme LLC
NCT06312176
 
 
 
 

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery 

Sponsor: Merck Sharp & Dohme LLC
NCT06393374
 
 
 
 

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/​Metastatic Disease (FourLight-3) 

An interventional, Open-label, Randomized, Multicenter Phase 3 Study of PF-07220060 Plus Letrozole Compared to CDK4/6 Inhibitor Plus Letrozole in Participants Over 18 Years of Age With Hormone Receptor (HR)-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Who Have Not Received Any Prior Systemic Anticancer Treatment For Advanced/Metastatic Disease (FOURLIGHT-3)

Sponsor: Pfizer
NCT06760637
 
 
 
 

A Study of Amivantamab and FOLFIRI Versus Cetuximab/​Bevacizumab and FOLFIRI in Participants With KRAS/​NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3) 

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Sponsor: Janssen Research & Development, LLC
NCT06750094
 
 
 
 

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma

Sponsor: Regeneron Pharmaceuticals
NCT06246916
 
 
 
 

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/​waveLINE-011)

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
 
Sponsor: Merck Sharp & Dohme LLC
NCT06890884
 
Learn More
 
 
 

A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

Sponsor: Regeneron Pharmaceuticals
NCT06091254
 
 
 
 

A Phase 1/​2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway 

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway

Sponsor: Bristol-Myers Squibb 
NCT05578092
 
 
 
 

First-in-human Study of DB-1305/​BNT325 for Advanced/​Metastatic Solid Tumors 

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors

Sponsor: DualityBio Inc.
NCT05438329
 
 
 
 

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

Sponsor: Seagen Inc. (Pfizer)
NCT04389632
 
 
 
 

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors (AURORAS-1) 

A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Sponsor: Erasca, Inc.
NCT06983743
 
 
 
 

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) 

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Inhibrx Biosciences, Inc
NCT04198766
 
 
 
 

A Study of YL201 in Patients with Advanced Solid Tumors

A Phase 1, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients with Advanced Solid Tumors

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
NCT05434234
 
 
 
 

A Study to Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

A Randomized, Open-label Study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Sponsor: Shanghai Henlius Biotech
NCT05468489

Learn More

 
 
 

Metastatic Pancreatic Ductal Adenocarcinoma Study

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Sponsor: Panbela Therapeutics
NCT05254171

Learn More

 

 

Relapsed/Refractory Follicular Lymphoma Study

Symphony-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

Sponsor: Epizyme, Inc
NCT04224493

Learn More

 
 

Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Study

A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Daiichi Sankyo, Inc
NCT04042701

Learn More